Results of an open multicenter non-interventional study of clinical efficacy and tolerability of etoricoxib in osteoarthritis and nonspecific back pain with additional evaluation of the effect of the drug on the «central» manifestations of pain

Autor: A. E. Karateev, E. Yu. Polishchuk, E. S. Filatova, V. N. Amirdzhanova, V. A. Nesterenko, A. S. Potapova, S. I. Glukhova, A. M. Lila, A. V. Sarapulova, A. A. Mukhin, O. S. Lyusina, L. A. Levasheva, E. V. Kryukova, D. K. Klein, N. V. Kichai, M. A. Kabalyk, N. E. Dobrokhotova, Yu. Yu. Grabovetskaya, L. A. Blagodareva, E. V. Zonova, S. M. Zwinger, P. P. Popov
Jazyk: ruština
Rok vydání: 2022
Předmět:
Zdroj: Современная ревматология, Vol 16, Iss 2, Pp 34-42 (2022)
Druh dokumentu: article
ISSN: 1996-7012
2310-158X
DOI: 10.14412/1996-7012-2022-2-34-42
Popis: The formation of chronic musculoskeletal pain (MSP) is a multifactorial process, in its pathogenesis mechanism of central sensitization (CS) plays an important role.Objective: to evaluate the effectiveness of etoricoxib at a dose of 60 mg per day in diseases accompanied by moderate/severe chronic MPS, with an additional analysis of the effect of this drug on the manifestations of CS.Patients and methods. An open observational study, 790 patients (71.6% women, mean age 54.5±13.0 years) with osteoarthritis and chronic nonspecific back pain received etoricoxib 60 mg/day for 2 weeks. The dynamics of pain, dysfunction, fatigue, sleep disturbances, general health assessment (GHA) on a numerical rating scale (NRS 0–10), as well as signs of CS according to part A of the CSI questionnaire were assessed.Results and discussion. After 2 weeks, the intensity of pain during movement, at rest and at night decreased on average by 58.8±24.1, 69.7±32.6 and 70.1±32.8% respectively; functional insufficiency by 58.2±22.5%, fatigue by 52.2±25.8%, GHA by 50.0±22.6%, sleep improvement by 54.3±25.8% was observed (p
Databáze: Directory of Open Access Journals
Externí odkaz: